Search | Clinical Trials Finder

Conditions: Drug Resistant Epilepsy, Drop Seizures, Generalized Tonic Clonic Seizure, Complex Partial Seizure, Fall Due to Seizure
Interventions: Hövding inflatable helmet; Device
Lead sponsor: Michael A. Gelfand, MD, PhD; Other
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Epilepsy
Interventions: CX-8998; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 16 Years to 55 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Little Rock, Arkansas • Tampa, Florida • Lexington, Kentucky + 4 more

Conditions: Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy, Seizures
Interventions: Ethosuximide, Lamotrigine, Valproic acid; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 30 Months to 13 Years
Enrollment: 453 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2016
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 28 more

Conditions: Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions: Placebo, Vanquix Auto-Injector (Diazepam Injection); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 86
States / cities: Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more

Conditions: Epilepsies, Myoclonic
Interventions: Placebo, Lorcaserin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more

Conditions: Autistic Disorder, Seizures, Irritability
Interventions: N-Acetyl Cysteine (NAC); Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 6 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Dravet Syndrome, Lennox Gastaut Syndrome, Epileptic Encephalopathy
Interventions: ZX008 (Fenfluramine Hydrochloride); Drug
Lead sponsor: Zogenix, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 26
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 23 more

Conditions: Dravet Syndrome
Interventions: ETX101; Drug
Lead sponsor: Encoded Therapeutics; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Miami, Florida + 8 more

Conditions: Absence Epilepsy, Childhood, Absence Seizures, Absence Epilepsy, Epilepsy in Children, Staring, Seizures
Interventions: Eysz Hyperventilation Recorder; Device
Lead sponsor: Eysz, Inc.; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 65 participants
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Epilepsy
Interventions: GW273225; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 30
States / cities: Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 26 more

Conditions: Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
Interventions: TAK-935, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Seizures
Interventions: Cannabidiol Oral Solution; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: San Francisco, California • Miami, Florida • Pensacola, Florida + 8 more

Conditions: Epilepsy
Interventions: Cannabidiol; Drug
Lead sponsor: University of Utah; Other
Eligibility: 2 Years to 25 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Drug-Resistant Epilepsy, Epilepsy, Epilepsy (Treatment Refractory), Epilepsy Comorbidities, Epilepsy, Drug Resistant, Epilepsy, Generalized, Epilepsy, Focal
Interventions: Target optimization using LIFU, Serial LIFU stimulation; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Seizures Associated With EMAS
Interventions: GWP42003-P, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 7 more

Conditions: Focal Epilepsy
Interventions: BHV-7000; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 115
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 92 more

Conditions: Seizures, Primary Motor Cortex, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Adult, Brain Metastases From Extra-cranial Solid Tumors
Interventions: Levetiracetam (Keppra); Drug
Lead sponsor: Ayal A. Aizer, MD; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Refractory Status Epilepticus
Interventions: Perampanel; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Epilepsy, Seizure Disorder, Neurologic Disorder, Rare Diseases
Interventions: Clinical care and quality improvement; Other
Lead sponsor: Epilepsy Foundation of America; Other
Eligibility: Not listed
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2099
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Epilepsy, Monotherapy
Interventions: Lacosamide, Carbamazepine-Controlled Release; Drug
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 16 Years and older
Enrollment: 888 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 15
States / cities: Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 12 more

Conditions: Focal Onset Seizure, Primary Generalized Epilepsy
Interventions: 30mg PRAX-628; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 8
States / cities: Phoenix, Arizona • Miami Lakes, Florida • Bethesda, Maryland + 5 more

Conditions: Dravet Syndrome
Interventions: ZX008 (Fenfluramine Hydrochloride); Drug
Lead sponsor: Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.; Industry
Eligibility: 2 Years to 35 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 24
States / cities: Phoenix, Arizona • Tucson, Arizona • Orange, California + 20 more

Conditions: Depression, Delirium, Seizures, Cognitive Disorders
Interventions: Ketamine, Electroconvulsive Therapy; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Infantile Spasms
Interventions: Spasm Vision; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: Up to 2 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Novel Helmet Design in Patients With Seizures

CX-8998 for Absence Seizures

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

Treatment Resistant Epilepsy and N-Acetyl Cysteine

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings

GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy

Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy

Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

Long-term Safety and Tolerability of BHV-7000

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

Epilepsy Learning Healthcare System (ELHS)

Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia

Artificial Intelligence-based Video Analysis to Detect Infantile Spasms